Skip to main
XRN

XRN Stock Forecast & Price Target

XRN Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 0%
Buy 50%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Chiron Real Estate is well-positioned for growth in the senior housing sector due to the increasing demand and limited supply caused by the pandemic. The company's strategic focus on senior housing and active adult housing, as well as its partnership in a 132-home community, demonstrates its commitment to this sector. While there may be risks, the company's positive financial results and transition to a growth-oriented platform suggest potential for continued success.

Bears say

Chiron Real Estate is undergoing a major overhaul of its portfolio, with a shift towards a senior housing operating properties (SHOP) model. This change in strategy introduces execution risks, but the company's leadership has the experience and bandwidth to pull it off. However, this transition may lead to negative FFO growth in 2027, and there is a possibility of competition from other REITs also pursuing the SHOP model. Additionally, Chiron is a relatively small REIT with limited trading liquidity, which could limit its investor audience. While the demographic story of an aging population supports demand for senior housing, the company's leverage and liquidity metrics need to be closely monitored, as well as the pace and size of their future dispositions and acquisitions.

XRN has been analyzed by 4 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 50% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Global Medical REIT Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Global Medical REIT Inc (XRN) Forecast

Analysts have given XRN a Hold based on their latest research and market trends.

According to 4 analysts, XRN has a Hold consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Global Medical REIT Inc (XRN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.